Biocon subsidiary acquires Chennai-based biological research facility from Pfizer Healthcare
Biotechnology major Biocon on Tuesday said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount.
Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement.
Also read:- Biocon acquires Pfizer RnD facility to boost biosimilars portfolio
“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said.
This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added.
The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories.
The facility is expected to be operational in a few months post qualification and will house over 250 scientists.
This acquisition provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of its biosimilars portfolio, the company said.
Also read:- Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru
At present, the company has an R&D centre at Bengaluru.
Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.
Biocon shares were trading 0.64 percent higher that their previous close at Rs 226.85 on the BSE.
Biocon Biologics has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement.
Also read:- Biocon acquires Pfizer RnD facility to boost biosimilars portfolio
“The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said.
This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added.
The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories.
The facility is expected to be operational in a few months post qualification and will house over 250 scientists.
This acquisition provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of its biosimilars portfolio, the company said.
Also read:- Biocon gets USFDA Form 483 with 8 observations for 2 new facilities in Bengaluru
At present, the company has an R&D centre at Bengaluru.
Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.
Biocon shares were trading 0.64 percent higher that their previous close at Rs 226.85 on the BSE.
BengaluruBioconBiocon Biologicsbiological research facilitybiosimilars portfolioBiotechnologyCEOChennaiChristiane Hamacherglobal developmentPfizer HealthcareR&DTICEL Bio Park
Source : PTIMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd